Private capital still betting on medtech as VC shifts to late-stage deals

Medtech private investment is increasingly polarized, as record funding for scaled platforms comes at the expense of early-stage innovation, which is struggling to keep pace. Public markets have reemerged as the sector’s main exit engine, with a wave of IPOs offsetting muted... See more